Efficacy and safety of octreotide treatment for diazoxide‐unresponsive congenital hyperinsulinism in China
ABSTRACT Importance Octreotide is an off‐label medicine for congenital hyperinsulinism (CHI), but is currently widely used for treatment of patients with CHI. Thus far, variable efficacy and adverse effects have been reported for octreotide. Objective The present study evaluated the efficacy and saf...
Main Authors: | Bingyan Cao, Wu Di, Chang Su, Jiajia Chen, Xuejun Liang, Min Liu, Wenjing Li, Xiaoqiao Li, Chunxiu Gong |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-03-01
|
Series: | Pediatric Investigation |
Subjects: | |
Online Access: | https://doi.org/10.1002/ped4.12175 |
Similar Items
-
A novel mutation of gene in a patient with diazoxide-unresponsive congenital hyperinsulinism
by: Ji Sook Park, et al.
Published: (2016-11-01) -
Congenital hyperinsulinism associated with Hirschsprung’s disease—a report of an extremely rare case
by: Takeshi Shono, et al.
Published: (2020-01-01) -
Congenital hyperinsulinism: current status and future perspectives
by: Tohru Yorifuji
Published: (2014-06-01) -
Neonatal congenital hyperinsulinism in Indonesia
by: I.Made Arimbawa, et al.
Published: (2021-01-01) -
Congenital hyperinsulinism: diagnostic and management challenges in a developing country – case report
by: Cheri Mathews John, et al.
Published: (2017-12-01)